Same Product Different Regulatory Approach Around the World: Glatiramer Acetate
Abstract
Complex drugs may be either biological, if the active ingredients are derived from a biological source, or non-biological, if obtained by chemical synthesis. In both cases, their quality depends considerably on the manufacturing process. For Non Biological Complex Drugs (NBCDs), in particular, complexity may arise either from the active substance, as in the case of glatiramer acetate (GA), or from other sources, such as the formulation, as in the case of liposomes (Figure 1) (1). GA is approved, in the US and the EU, as a diseasemodifying treatment for patients with relapsing forms of Multiple Sclerosis. It is a heterogeneous mixture of not fully characterized synthetic polypeptides, containing L-alanine, L-lysine, L-glutamic acid, L-tyrosine in the constant molar ratio 0.43:0.34:0.14:0.09, with and average molecular weight from 5 to 9 kDa and distribution range from 2.5 to 20 kDa (2). The amino acid sequences are not completely random, being the result of both the physicochemical properties of the starting materials and the fundamental reaction scheme. However, they are not completely conserved from batch to batch, even when the process is tightly controlled. Indeed along with conserved characteristics such as amino acid molar ratio other characteristics such as the specific amino acid sequences will show batch-to-batch variability (1). To address this complexity, for the marketing of GA copies, US and EU regulatory agencies have chosen a generic approach integrated with…
Read the paper
Related studies
- Diagnosis and management of glutaric aciduria type I – revised recommendations
- EZH2 Codon 641 Mutations are Common in BCL2-Rearranged Germinal Center B Cell Lymphomas
- Consensus guidelines for the diagnosis and management of pyridoxine‐dependent epilepsy due to α‐aminoadipic semialdehyde dehydrogenase deficiency
- Systemic Metabolomic Changes in Blood Samples of Lung Cancer Patients Identified by Gas Chromatography Time-of-Flight Mass Spectrometry
- Human OTULIN haploinsufficiency impairs cell-intrinsic immunity to staphylococcal α-toxin
- Discovery of Novel Recurrent Mutations in Childhood Early T-Cell Precursor Acute Lymphoblastic Leukemia by Whole Genome Sequencing - a Report From the St Jude Children's Research Hospital - Washington University Pediatric Cancer Genome Project
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.